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Abstract 
Background Patients with Systemic Lupus Erythematosus (SLE), a systemic autoimmune 
disease, have an elevated risk of developing cardiovascular disease compared to their healthy 
counterparts. The chronic inflammatory state in these patients heighten their risk of 
developing premature atherosclerosis and subsequent progression to coronary artery 
calcification (CAC). CAC increases the risk of coronary events occurring and it is characterised 
by the osteogenic transdifferentiation of coronary artery smooth muscle cells (CASMCs) and 
consequent deposition of hydroxyapatite minerals within the extracellular matrix. Runx2 is a 
potent regulator of osteogenic differentiation of CASMCs and its expression is regulated by 
microRNAs (miRNA or miR). CAC is a major clinical problem, but limited treatment options are 
available. This study investigates whether miRNA alteration affects mineralisation in an in vitro 
calcification assay model. 
Aims This study aimed to validate the association of miR-3148 with Runx2-driven CAC and 
investigate the effects of different miRNAs on genes involved in CAC in CASMCs.  
Methods Human Embryonic Kidney (HEK) 293T cells were used to produce high-titre lentiviral 
vectors for miR-3148 and its sponge, and pLL3.7 plasmid. Human Coronary Artery Smooth 
Muscle Cells (CASMCs) were transfected with lentivirus and cultured in osteogenic media. The 
level of miRNA-3148 in cells and microvesicles derived from TNF-α stimulated CASMCs in vitro 
was determined. Alizarin Red S staining and quantification was used to identify changes in 
mineralisation between the different groups. Gene expression analysis was conducted. 
Results miR-3148 levels were higher in TNF-α stimulated CASMCs compared to control. Stable 
transfection was observed in lentivirus transfected cells. A lower level of calcium deposits was 
observed in cells transfected with miR-3148 lentivirus in comparison to empty vector control 
(P = 0.00201) and transfection with miRNA-3148 sponge. miRNA-3148 also lowered Runx2-
gene expression in relation to control and miR-3148 sponge at day 4.  
Conclusion The current study demonstrates that overexpression of miR-3148 reduces the level 
of mineralisation via Runx2 in vitro, suggesting a protective role for miRNA-3148 against 
osteogenic transdifferentiation of CASMCs. These data imply the possibility of using 
microvesicles and/or miRNAs for drug therapy in the management or treatment of CAC. 
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1 Introduction 
1.1 Systemic Lupus Erythematosus and Cardiovascular Disease 
Systemic Lupus Erythematosus (SLE) is a prototypic, systemic autoimmune disease that mainly 
affects women of childbearing age, with significant mortality and morbidity. An elevation in 
the prevalence of cardiovascular disease (CVD) has been observed in patients with SLE, and it 
is the leading cause of death in this patient group (Sinicato et al., 2013). A recent study shows 
a 2.7-fold increased risk of an SLE patient developing acute CVD events relative to the expected 
value based on a Framingham risk score (Magder and Petri, 2012). The reason for this 
heightened rate of CVD is not completely understood, but factors contributing to CVD include 
medications such as glucocorticoids, inflammation and the effects of cytokines (Sinicato et al., 
2013). Results from our group have highlighted significant factors that should be taken into 
consideration when treating SLE patients (Edwards et al., 2018).  
CVDs refer to dysfunctions in the heart or vasculature, including coronary heart disease, 
hypertension, congenital heart disease, peripheral artery disease and heart failure. 
Dyslipidaemia (observed in 36% to over 60% of SLE patients) (Urowitz et al., 2008) and 
consequent endothelial dysfunction (54.8% of SLE patients in comparison to 26.3% of control 
population) is frequently observed in women with SLE (El-Magadmi et al., 2004), contributing 
to both clinical and subclinical CVD (Kiani et al., 2011). These conditions include arterial 
hypertension (33% to 74%) (Sabio et al., 2011) subclinical atherosclerosis (6-fold increased risk 
in SLE patients compared with control population) (Kiani et al., 2011; Wu et al., 2016), carotid 
plaque, arterial stiffness (Parker et al., 2014) and coronary artery calcification (detected in 30% 
to 58% of SLE populations) (Parker et al., 2014; Kiani et al., 2015), the pathology of focus in this 
study. Deposition of coronary calcium is an independent predictor of both short- and long-
term cardiac events (Chang et al., 2009). The increased risk of developing atherosclerosis in 
autoimmune diseases is suggested to be due to persistent inflammation in the vasculature 
involving various inflammatory mediators such as leucocytes, cytokines and chemokines, and 
long-term exposure to steroid therapy (López-Pedrera et al., 2010; McMahon et al., 2011). 
Atherosclerosis is a vascular inflammatory disorder where accumulation of lipids, 
inflammatory cells, platelets and vascular smooth muscle cells (VSMCs) (principal cell type in 
the medial layer of the arterial wall) is triggered by endothelial dysfunction, and VSMC 
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proliferation and migration to the intimal layer occurs (Paudel et al., 2016). There is an increase 
in thickness of the intima-media and carotid plaque formation in these patients, in comparison 
to control (Shoenfeld et al., 2005; López-Pedrera et al., 2010). 
1.2 Vascular Calcification 
Coronary artery calcification (CAC) refers to vascular calcification that occurs in the coronary 
arteries. Vascular calcification is a highly regulated, active process in which coronary artery 
smooth muscle cells (CASMCs) undergo apoptosis and sequential transdifferentiation into 
osteogenic-like cells, leading to deposition of hydroxyapatite minerals within the vessel wall 
(Evrard et al., 2015; Durham et al., 2018). Triggers for apoptosis includes interaction of CASMCs 
with inflammatory cells expressing cell surface death ligands and secretion of pro-apoptotic 
cytokines such as tumour necrosis factor (Iyemere et al., 2006). An in vivo study by Aikawa and 
colleagues (2007) confirms atherosclerosis-related vascular calcification to be an inflammatory 
disease due to the involvement of macrophage preceding osteogenic activity within the 
atherosclerotic plaque. Additionally, work conducted by Demer and colleagues (Watson et al., 
1994; Tintut et al., 2000; Parhami et al., 2002) demonstrated cytokines such as tumour necrosis 
factor-α (TNF-α), interleukins-1β, -6 and -8, and transforming growth factor-β from 
macrophages to stimulate osteogenic differentiation and mineralisation in vitro. 
At the cellular level, vascular calcification shares many similarities with osteogenesis, and is 
promoted by endothelial damage and dysfunction from inflammation as a result of oxidative 
stress (Fakhry et al., 2017). Inflammation can be an indicator of amplified oxidative stress and 
evidence to support the involvement of oxidative stress in atherosclerosis in animal studies is 
available (Steinberg, 2009). Chronic inflammation seen in SLE patients is indicative of elevated 
conditions of oxidative stress, causing vascular imbalances that can stimulate atherosclerosis 
formation, followed by osteoblast or chondrocyte maturation and calcium deposition (Fakhry 
et al., 2017). Furthermore, studies have documented that inflammation can trigger 
osteoblastic activity, resulting in mineralisation in the early stages of atherosclerotic plaque 
formation (Demer and Tintut, 2003; Aikawa et al., 2007).  
Within the vasculature, the role of endothelial cells and VSMCs are crucial in maintaining 
vascular tone and homeostasis (Iyemere et al., 2006; Chang et al., 2014). VSMCs are known to 
have a plasticity function. These cells maintain normal blood pressure by cycles of contraction 
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and relaxation which changes vessel diameter and allow haemodynamic regulation (Chang et 
al., 2014; Frismantiene et al., 2018). In addition, VSMCs provide resistance to mechanical stress 
and structural support in the blood vessels, as well as contribute to smooth muscle and vessel 
repair by reversible differentiation, acquiring a reparative phenotype (Owens et al., 2004; 
Frismantiene et al., 2018). This vascular wall renewal or repair of injury to the vessel occurs 
constantly at a low rate, but this VSMC plasticity is compromised under conditions which lead 
to failure of the controlling mechanisms (Frismantiene et al., 2018). This increases the risk of 
developing atherosclerotic plaques (Owens et al., 2004). Upon progression of the disease, 
calcium phosphate crystals form within the intimal layer, similar to the crystals detected in 
bone (Iyemere et al., 2006). Subsequently, the disease is driven by a positive feedback loop of 
mineralisation and inflammation (Nadra et al., 2005).  
VSMCs also participate in maintaining and remodelling of the extracellular matrix (ECM) of 
blood vessels (Durham et al., 2018). The ECM predominantly contains various types of elastin 
fibres and collagen, and many studies show an association between degradation of the ECM 
and atherosclerosis (Chen et al., 2018). Under pathological conditions VSMCs transform into 
osteo/chondrocytic-like cells with macrophage- and lipid-rich atherosclerotic lesions. There is 
a reduction in elasticity of the vessel wall which disrupts the normal haemodynamic of the 
vessel (Shanahan et al., 1999; Iyemere et al., 2006). This loss of arterial elasticity and stiffness 
has been associated with substantial cardiovascular mortality and morbidity, relating to 
hypertension, stroke and myocardial infarction (Manzi et al., 1997; Demer and Tintut, 2008). 
Many studies and disease models have used VSMCs and vascular tissues, but the biology of 
these cells in poorly understood, hence why there has not been any success in treating or 
preventing VSMC-related conditions (Frismantiene et al., 2018). Morphological changes are 
observed in in vitro cultures of VSMCs, referred to as phenotype switching or transition, in 
response to different environments and treatments (Owens et al., 2004) and this includes 
transdifferentiation to osteogenic-like cells. 
Typically, young women are at a low risk of early-onset CAC, but the opposite is seen in young 
women with SLE (Kiani et al., 2015) and this cannot be explained by traditional risk factors 
(McMahon et al., 2011). Comparatively, a study by Kao et al. (2008) found an increased 
prevalence of asymptomatic CAC in non-diabetic women with SLE (48%) compared to age- and 
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race-matched healthy controls (35%). Currently, the mechanism of this process in SLE patients 
is poorly understood. Regardless of its substantial clinical impact, no medical therapies exist to 
prevent or treat CAC. Identification of the pathways governing this disease can help in 
producing a novel therapeutic strategy and will be the focus of this study. 
1.3 Microvesicles 
Microvesicles (MV) are small membranous structures released from many cell types through 
either an exocytosis “budding” process (Schiro et al., 2014; Buendía et al., 2015) or an 
endosomal pathway via fusion of multivesicular bodies with the plasma membrane and 
exosome release (Krohn et al., 2016). This occurs in response to cell activation, stress or 
apoptosis triggered by inflammatory cytokines, cardiovascular risk factors and/or complement 
activation (Burger et al., 2013; Goettsch et al., 2013; McCarthy et al., 2016). During this 
process, the MV takes a part of the cell’s contents with it, safely packaged within a specific part 
of the membrane, consequently the MV contains specific proteins from the parent cell but in 
different amounts (Majeska and Wuthier, 1975; Paudel et al., 2016). Furthermore, the stimulus 
that triggers MV release determines the different and distinctive role of the MV in disease 
(McCarthy et al., 2017). The vesicles have a metabolically active outer membrane, giving 
protection to its cytoplasmic components which consists of proteins, microRNA (miRNA or 
miR) and other components from the paternal cell (Brodsky et al., 2004; New et al., 2013; 
Buendía et al., 2015). The contents of a MV dictates its function and allow for participation in 
both physiological and pathological systems (New and Aikawa, 2013). In addition, MVs partake 
in the modulation of cell apoptosis and proliferation, maintaining vascular homeostasis and 
inflammation, which explains their involvement in the pathogenesis of immune-mediated 
diseases as shown in a prospective study carried out by our group (Parker et al., 2014; 
McCarthy et al., 2017). 
MVs are able to mediate communication between cells and allow exchange of genetic 
information, as well as participate in adaptive immune responses (New and Aikawa, 2013). 
Moreover, these vesicles can regulate function of target cells, depending on the stimulus which 
triggered MV release, by delivering and transferring their contents to several recipient cells 
(Mause and Weber, 2010; Jansen et al., 2013; Pan et al., 2016). The exchange of molecules 
occurs as the vesicle binds to surface receptors on the target cell with endocytosis by recipient 
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cells and fusion with the membranes, allowing the vesicle to release its content into the target 
cell cytosol (Goettsch et al., 2013).  
Increased endothelial cell-derived MVs (EMVs, 100nm to 1µm in diameter) have been 
observed in patients with traditional CVD risk factors (Preston et al., 2003; McCarthy et al., 
2016), and EMVs predict adverse outcomes in patients with CVD (Sinning et al., 2011; Parker 
et al., 2014; Paudel et al., 2016). Evidence shows that EMVs are able to mediate intracellular 
signalling through their ability to transfer bioactive molecules to recipient cells, and they show 
paracrine and autocrine actions on vascular cells (Distler et al., 2005; McCarthy et al., 2016). 
In addition, previous work by our group found significantly higher levels of EMVs in patients 
with active and low-disease activity SLE, in relation to endothelial dysfunction, compared to 
controls (Parker et al., 2014; Schiro et al., 2014). EMVs are also present in healthy controls, but 
at low levels. Further research also demonstrated lowered cardiovascular risk as a result of 
reducing the number of circulating EMVs by immunosuppressive therapy (Parker et al., 2014). 
However, it is unclear whether the composition of MVs can directly stimulate osteogenic 
differentiation of CASMCs and subsequent mineralisation. 
1.4 MicroRNAs 
It has been established that the majority of the genome is transcribed into ribonucleic acid 
(RNA) and most of this transcriptome produces regulatory RNA, important in the regulation of 
biological processes (Mattick and Makunin, 2006; Condorelli et al., 2014). Consequently, a 
huge part of the genome is dedicated for the production of regulatory non-protein coding 
RNAs (ncRNAs), small interfering RNAs (siRNAs) and miRNAs (Mattick and Makunin, 2006). The 
miRNA family is known to perform a role in regulating proteins involved in the 
pathophysiological response to stress (Leung and Sharp, 2010). In addition, miRNAs constitute 
an ample ncRNA species with around 2,000 miRNAs in humans (according to miRbase; 
http://www.mirbase.org) coded for by sections within the introns of coding or non-coding 
transcripts synthesised by RNA polymerase II, outnumbering phosphates and kinases, 
demonstrating their influence on regulating cellular processes (Mattick and Makunin, 2006; 
Leung and Sharp, 2010; Goettsch et al., 2013). More than 60% of all mammalian mRNAs are 
predicted targets of miRNAs (Friedman et al., 2009). 
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miRNAs are single-stranded, non-coding RNAs, 18 to 24 nucleotides in length. They negatively 
regulate post-transcriptional gene expression by complementary binding to target miRNA 3’- 
untranslated region (3’-UTR), inhibiting translation and/or degrading the mRNA, and 
therefore, causing gene silencing (Wahid et al., 2010; Goettsch et al., 2013; Wojciechowska et 
al., 2017). Furthermore, this forms a 3-dimensional communication between miRNA and 
mRNA within a cell, changing in response to age and pathophysiological processes (Condorelli 
et al., 2014). This function allows miRNAs to act as genetic switches or fine-tuners for a diverse 
range of biological processes, and it has been reported that miRNA dysregulation can impair 
cellular function and aid in disease progression (Goettsch et al., 2013). 
Typically, miRNAs are intracellular but can be released into the bloodstream in combination 
with proteins or encapsulated by microvesicles formed from the plasma membrane, or 
expelled by membrane shedding of the cell and carried to different sites where they interact 
with other cells (Condorelli et al., 2014; Wojciechowska et al., 2017). miRNAs have been 
implicated in playing an important role in the pathophysiology of CVDs, including the control 
of VSMC proliferation and maturation, neoangiogenesis, vasculogenesis and endothelial 
function (reviewed in Condorelli et al., 2014). A series of miRNAs have been demonstrated to 
regulate osteoblast differentiation and mineralisation (Hu et al., 2010; Fakhry et al., 2013). The 
potential role of miRNAs in SLE-related CAC will be investigated in this research project. 
Consequently, examining the effects of over- or under-expression of miRNAs can be useful in 
determining the therapeutic targets for prevention and treatment of CAC. miRNA levels can 
be modified within in vitro models of calcification by two approaches: mimicking miRNA 
function (over-expression), or by silencing its action (under-expression) (Condorelli et al., 2014; 
Wojciechowska et al., 2017). miRNA expression has been shown to be inhibited using 
artificially designed transcript decoys called “sponges” which contain miRNA-binding sites in 
the 3’-UTR of non-toxic gene and can deplete the cell of free and active target miRNA (Leung 
and Sharp, 2010; Dangwal and Thum, 2014; Nguyen and Chang, 2017). 
A study by our group on miRNA levels in patients with SLE has shown a higher level of miR-
3148 compared to controls in this population. This indicated a potential role for miR-3148 in 
the inflammatory process associated with this disease and potentially the subsequent 
formation of mineralised matrix in the coronary arteries. In addition, a bioinformatics analysis 
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using DIANA-TarBase algorithms (http://carolina.imis.athena-
innovation.gr/diana_tools/web/index.php?r=tarbasev8/index)  predicted that the following 
miRNAs are involved in the regulation of genes coding for proteins that have been previously 
linked to the pathways leading to VC: miR-30d-5p, miR-320a and miR-3148 (Vlachos et al., 
2015). These miRNAs were then selected to be investigated in the current study. 
1.5 MicroRNA Target Genes involved in Calcification 
The development and maintenance of normal homeostasis of the vasculature requires 
accurate regulation of a series of genes associated with multiple signalling pathways, and the 
initiation and advancement of vascular diseases are often caused by abnormalities in signalling 
between these genes. Since VSMCs exhibit high phenotypic diversity, the transcriptional 
regulation of these cells is also very complex, and differentiation is driven by multiple 
transcriptions factors. Expression of multiple genes can be affected by a single miRNA 
(convergent miRNA pathway), and multiple miRNAs may compete or interact with each other 
to regulate a single mRNA with multiple miRNA binding sites in the 3’-UTR region (divergent 
miRNA pathway) (Condorelli et al., 2014). This explains why only a small number of targets 
may cause wide-ranging changes in biological responses and phenotypes (Anglicheau et al., 
2010; Goettsch et al., 2013; Katano et al., 2017). 
Runt-related transcription factor 2 (Runx2), also known as Cbfa1 or AML3, plays a crucial role 
in osteoblast differentiation and chondrocyte maturation in bone (Sun et al., 2012). It regulates 
gene expression of proteins involved in bone mineralisation and bone matrix proteins, 
including osteopontin, osteocalcin and receptor activator of nuclear factor κ-B ligand (RANKL) 
(Zamurovic et al., 2004; Leopold, 2014), affecting differentiation and maintenance of 
osteoprogenitor cells (Zhang et al., 2011). Runx2 expression in vascular cells under normal 
physiological conditions is typically low, but the expression is elevated in calcified vascular 
tissue samples from atherosclerotic plaques (Sun et al., 2012). Research shows that aberrant 
expression of Runx2 in CASMCs induces osteo-/chondrogenic phenotype in these cells (Speer 
et al., 2010). Lin and colleagues (2015) demonstrated the absence of Runx2 in VSMCs isolated 
from Runx2 knockout mice and they did not calcify under high-phosphate conditions in vitro. 
In addition, these Runx2 knockout mice were less susceptible to phosphate-induced 
calcification compared to control. Moreover, Runx2 overexpression has been acknowledged in 
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atherosclerotic calcified human vascular tissue specimens (Tyson et al., 2003; Aikawa et al., 
2007) and in calcified aortic smooth muscle cells in mice (Steitz et al., 2001), stressing its role 
in CAC. These findings suggest that pathways controlling Runx2 expression are potential 
targets for prevention and therapy of vascular calcification. 
Bone morphogenetic  proteins (BMPs) are a group of growth factors which are crucial in the 
development of the vasculature and are involved in vascular disease (K. I. Boström, 2016). It is 
known that BMPs are able to activate osteogenic differentiation of cells (K. Boström et al., 
1993) and have been associated with atherosclerosis. BMP2 is a pro-calcifying stimulus which 
upregulates intracellular levels of inorganic phosphate and triggers the expression of Runx2 
(Nanoudis et al., 2017). In vitro and in vivo studies in bone tissue show that inhibition of BMP2 
prevents differentiation of osteoblasts and bone formation and protects against 
atherosclerosis and vascular calcification in vascular tissue (Evrard et al., 2015). 
Further genes that have been associated with calcification include Sirtuin 1 (Sirt), a gene 
associated with cell longevity and a marker for cell senescence through regulation of cell cycle, 
metabolism and apoptosis (Takemura et al., 2011). Sox9 (SRY [sex-determining region Y]-box 
9 related transcription factor) is another gene of interest in calcification. It is a chondrogenic 
regulator primarily expressed in resting and proliferating chondrocytes which is known to 
interrupt the activity of Runx2 (Zhang et al., 2012; Loebel et al., 2015). Finally, matrix 
metallanoproteinase-16 (MMP16) is a part of a group of proteolytic enzymes that are able to 
regulate and partake in extracellular matrix remodelling and degradation. Under pathological 
conditions, MMPs are considered to participate in events leading to the changes in 
proliferation and migration of VSMC and vascular collagen and/or elastin content, potentially 
leading to an increase in arterial stiffness (Peeters et al., 2017). 
All three miRNAs, -30d-5p, 320a and 3148, have been found to target the calcification protein 
regulator Runx2 and the transcription factor SOX9. Only miR-3148 was found to target BMP2, 
but with a very low rank (number 3501). miR-3148 and -30d-5p target Sirt1. The gene coding 
for MMP16 was not shown to be a target of any of the miRNAs according to the bioinformatics 
analysis results, but since this group of metallanoproteases have been considered to play a 
potential role in arterial stiffness, the changes in the level of expression of this enzyme was 
determined in this study also. 
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1.6 Gateway® Cloning Technology for use in Protein Functional Analysis 
The Gateway® Cloning technology is a recombinational cloning system, an alternative to 
restriction enzyme cloning, and is able to produce high-throughput parallel generation of 
Expression Clones in vitro (Doyle, 2009). The system is based on the recombination between 
attachment sites (att sites); B, P, L and R. and there is no net loss or gain of nucleotides during 
this reaction. However, the DNA fragments flanking the recombination sites are switched 
resulting in att sites that are hybrid sequences containing nucleotides contributed by each 
parental vector, maintaining the reading frame register (Hartley et al., 2000). The target genes 
are flanked by two slightly different att sites and are unable to combine with each other, 
allowing the recombination reaction to occur while retaining the reading frame (Invitrogen, 
2003; Doyle, 2009). 
In this project, a Destination Vector (DV) with a lentiviral vector backbone was generated via 
the BP recombination reaction where the attB sites of the Expression Clones and attP sites of 
the donor vector recombine. The DV contains a Gateway® “cassette”, replacing the target 
gene, which encodes elements needed to express the gene of interest in the suitable system 
(i.e. E. coli), including resistance markers and promoters; chloramphenicol resistance gene and 
ccdB suicide gene (Doyle, 2009). The ccdB gene encodes CcdB protein which interferes with E. 
coli DNA gyrase, resulting in inhibition of the growth of these cells, making it a toxic gene 
(Bernard and Couturier, 1992). The consequential attR sites of the DV are able to recombine 
with the attL sites of Entry Clones in an LR reaction to produce an Expression Clone (as 
portrayed in Figure 1) (Invitrogen, 2003; Doyle, 2009).  
 
 
Figure 1 A diagram to represent the LR reaction in a Gateway Cloning System 
During the LR reaction, LR clonase is required; it facilitates the recombination of the attL sites of the Entry Clone with attR 
sites of the destination vector to create an Expression Clone with attB sites. 
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Consequently, a strain of ccdB resistant E. coli is required to promote growth of bacteria 
containing the DV and to eliminate non-recombinant vectors. The DV will then be recombined 
with an Entry Clone vector containing the gene of interest via the LR reaction, producing the 
Expression Clone containing the DV lentiviral backbone.  
The purpose behind constructing a DV of this nature is that it not only fulfils the requirement 
for this study, investigating the effects of the specific miRs selected, but will enable new 
lentiviral vectors to be produced by our group with ease and speed in the following three 
different ways: 
1. A plasmid with the gene of interest flanked by attL1 and attL2 sites and Kanamycin 
resistance could be purchased: 
The plasmid acts as the Entry Clone and is mixed with the DV (containing the suicide 
gene ccdB) in the presence of LR Clonase™ (Figure 1). Then clones would be selected 
for ampicillin resistance to isolate the putative lentiviral Expression Clone. 
2. PCR could be performed on the gene of interest with attB1 and attB2 sites added to 
primers: 
The PCR product is combined with donor vector pDONR™221 and incubated at 25°C for 
up to 24 hours. The DV is then added and selected for ampicillin resistance after 
incubation at 25°C for up to 24 hours. 
3. A plasmid with the gene of interest flanked by attB1 and attB2 sites and ampicillin and 
kanamycin resistance could be purchased: 
Perform BP recombination reaction with pDONR™221 and the purchased plasmid and 
select for kanamycin resistance from an overnight growth of bacterial culture. Extract 
DNA from a colony and perform the LR reaction with the DV, followed by selection for 
ampicillin resistance. 
1.7 Hypothesis 
This study tests the hypothesis that miR-3148 released from EMVs protects against the 
osteogenic differentiation of human CASMCs in vitro by targeting Runx2 gene. 
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1.8 Aims and Objectives 
The aim of this study was to validate the association of miR-3148 with EMV-driven and SLE-
related coronary artery calcification and explore the function of these possible regulators in 
disease progression. The effect of miR-3148 in the process of β-glycerophosphate-induced 
osteogenic differentiation of CASMCs was also evaluated. In addition, this study investigated 
the effects of altered levels of the following: miR-30d-5p, miR-320a and miR-3148, on genes 
involved in CAC in CASMCs. A DV was also be generated as a part of the Gateway® Cloning 
system to make cloning of lentiviral vectors in subsequent studies in the future effortless. 
2 Methodology 
2.1 Cell Culture and in vitro Calcification of Human Coronary Artery Smooth 
Muscle Cells 
Early Passage Human CASMCs (Caltag Medsystems, ZHC-3311) were used as the most 
appropriate cell of choice for this study as CASMCs are prone to calcification in cardiovascular 
disease patients and are widely used as an in vitro calcification model, as previously described 
by our group (Liu et al., 2011; Yan et al., 2011; Bartoli-Leonard et al., 2019). These cells were 
cultured in Smooth Muscle Cell Growth Medium 2 (SMC growth medium) (Promocell, C-
22262), supplemented with 5% Foetal Calf Serum (FCS), 2ng/ml basic fibroblast growth factor, 
5µg/ml insulin and 0.5ng/ml epidermal growth factor (Promocell, C-39262) in T75 cell culture 
flasks (ThermoFisher Scientific) at 37°C, 5% CO2, with media change twice a week. CASMCs 
used for this study were from the 5th to 8th passage. 
Early Passage Human Embryonic Kidney (HEK) 293T cells were used for transfection studies as 
they are the most widely accepted cell line for recombinant DNA technology and were cultured 
in Dulbecco’s Modified Eagle’s Medium (DMEM) (Lonza, BE12-614F), 10% FCS, 1% L-Glutamine 
(Corning, 15393631) and 1% Penicillin-Streptomycin (Lonza, 17-603E) in T75 cell culture flasks 
at 37°C, 5% CO2, and this was used as the regular culture medium. HEK 293T cells used for this 
study were from the 15th to 21st passage. 
At confluence (as shown in Figure 2), 8.7 x 106 cells in T75 flasks, the adhering cell monolayer 
was washed with 10 ml Phosphate Buffered Saline (PBS) (Lonza, BE17-512F) and then 2.5-3 ml 
of Trypsin EDTA (Lonza, BE17-161E) was added to dislodge the cells, all at 37°C. 5 ml of fresh 
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regular DMEM medium was then added to the cells to block the action of trypsin, and the cell 
suspension was centrifuged at 300 x g for 5 minutes, 21°C. The pellet was re-suspended in T75 
flasks in regular DMEM (for 293Ts) for future calcification experiments or in SMC growth 
medium (for CASMCs) for cell maintenance at a density of 4 x 105 cells/cm2, and incubated 
overnight at 37°C. High glucose DMEM was used for all experiments.  
For the calcification assay, 5 mmol/L β-glycerophosphate (βGP) and 2.6 mmol/L CaCl2 in DMEM 
(4.5 g/L glucose) was used to induce mineralisation of the cells which occurred at 15 to 18 days. 
CASMCs were seeded in SMC growth media in 6-well plates (Nunclon™ Delta Surface, 
ThermoFisher Scientific) at a density of 1.2 x 106 cells per well. The aim was to perform all 
experiments with technical duplicates and biological triplicates so that there would be at least 
n = 3 for statistical purposes. However, due to lack of time within this one-year study, and the 
challenges associated with growing human primary patient cells, this was not always possible. 
Therefore, n numbers are provided in each figure legend and statistical analysis was carried 
out when appropriate. Conclusions were not drawn when insufficient experiments were 
performed, but an inference could be made and this is taken into account in the discussion.  
Cells were treated with 500 µl lentiviral vector containing genes for the following miRNAs and 
their sponges: miR-30d-5p, miR-320a and miR-3148, and plasmid pLL3.7 used as the control, 
in osteogenic media. Media change on cells occurred twice a week for 18 days, or until the 
presence of calcific nodules (Liu et al., 2011). 
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Figure 2 Cells at confluence 
Cells were maintained in T75 flasks and transferred to T75/T175 flasks or 6-well plates. (A) Passage 3 Human Coronary 
Artery Smooth Muscle Cells at day 4 (B) Passage 5 Human Embryonic Kidney 293T cells at day 4.  
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2.2 Alizarin Red Staining and Quantification to Measure Mineralised Matrix 
Formation 
Alizarin Red S is a well established staining procedure to identify the presence and extent of 
calcium deposition in cultures of VSMCs. At 15-18 days, when calcific nodules were observed, 
media was aspirated from CASMCs and the cells were washed three times with PBS (1 ml/well) 
then fixed in 4% paraformaldehyde (700 µl/well) (Sigma-Aldrich, P6148) for 10 minutes at 
room temperature (RT). The cells were re-washed and stained with 1 ml 2% Alizarin Red S (ARS) 
(pH 4.2 with hydrochloric acid, Sigma-Aldrich, F5533) for 5 minutes at RT. The cells were 
washed with distilled water four times. To quantify mineralisation, the ARS stain was eluted 
using 1 ml of 10% formic acid (Sigma-Aldrich, F0507) for 5 minutes on a rocker and 200 µl of 
elution added in triplicate to a 96-well plate. Absorbance was measured at 414 nm (Liu et al., 
2011).  
2.3 Inflammation assay and Isolation of Microvesicles, miRNA Extraction, 
Reverse Transcription and Quantitative Polymerase Chain Reaction (RT-
qPCR) 
CASMCs were seeded in 6-well plates and treated after 24 hours with FCS-free DMEM (2 
ml/well), and at 48 hours with TNF-α (1 µl/ml) in DMEM (10% exosome free FCS). After 24 
hours of treatment with TNF-α the media was aspirated and centrifuged at 1,500 x g for 10 
minutes. The supernatant was then ultracentrifuged at 100,000 x g for 60 minutes (at 4°C) to 
isolate microvesicles. miRNA was extracted from the microvesicles and cells using a miRNA 
isolation miRNEASY kit (Qiagen, 217004) as per the manufacturer’s instructions. miRNA was 
reverse transcribed using miRCURY LNA RT kit (Qiagen, 339340) using SureCycler 8800 at 42°C 
for 60 minutes, followed by 95°C for 5 minutes. qPCR was conducted using miRCURY LNA 
miRNA PCR assay kit (Qiagen, 339306) as follows; 10 seconds at 95°C and 1 minute at 56°C for 
40 cycles. The primers for miR-3148 (U G G A A A A A A C U G G U G U G U G C U U) and Let-7a-
5p miRNA (U G A G G U A G U A G G U U G U A U A G U U) were used. All PCR amplifications 
were carried out using StepOnePlus system (Applied Biosystems). Quantification was 
performed using the 2-ΔΔCt method. 
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2.4 Vector Preparation: Electrophoresis and Plasmid Cloning by Restriction 
Enzyme Digest 
The online database National Centre for Biotechnology Information (NCBI) was used to 
produce the sequences for each miRNA (as shown in Table 1). 
 
Table 1 Sequences of artificially designed transcripts coding for the miRNAs 
The sequences for each miRNA are highlighted in “bold” and the flanking regions are 100bp of the sequence 
surrounding the gene in the genome. 
 
DNA Sequence NCBI Gene ID 
hsa-miR-30d-5p T C T A T T G T T C A G C A C T A G A A A T T A T A T A A A T T A T T A G 
C T G A A G A T G A T G A C T G G C A A C A T T T A T G T C T G T T C C T 
C C T C T T A A A T T T C T T G T T C A G A A A G T C T G T T G T T G T A A 
A C A T C C C C G A C T G G A A G C T G T A A G A C A C A G C T A A G C 
T T T C A G T C A G A T G T T T G C T G C T A C C G G C T A T T C A C A G 
A C A T C C T C T T G A T A T A A T T C T G T C C C G G A G T G G A G T T 
G A G G A G G C T A T A A A A T G T G T G G G A A A A C C T C A G A A A 
T C T T T A G C T G C A T T C T C G A G G 
407033 
hsa-miR-320a T C G G C G G A A G T C T G C G T G G C A G G G C C T G G G C G C C G C 
C A T C T T G G C G C G G G G C G G A A G T G A C G T T A G G G G G G C 
G G G A C T G G G C C A C A G T A T T T A T C A G G C G G C G C T T C G 
C T C C C C T C C G C C T T C T C T T C C C G G T T C T T C C C G G A G T C 
G G G A A A A G C T G G G T T G A G A G G G C G A A A A A G G A T G A 
G G T G A C T G G T C T G G G C T A C G C T A T G C T G C G G C G C T C 
G G G G G T C T T G G C C T C C G G G C G G T G G C G T G G A G G C G C 
C A A G A T C A G G G T C C C G G G T T T T G T C G G C C A C C T C G A G 
G 
407037 
hsa-miR-3148 T C T C T T C C C A C A G G A A G G C A A T G T G T G G A A T G G A G A 
A G G C T G C T T C A G C A A C A T C C T C T C C C A T G C A C C T T A A 
A C G T C T C T T T C T T T C T C A G C T C C T T T C T G G A G T T A A G A 
T G G A A A A A A C T G G T G T G T G C T T A T T G A T G T A G C C A A 
C A A G C A T A C A T C A G T T T T T T C C A A C T T A A C T C C A G T A 
T T T T C C C C A A T T C A T C C T G A A A T T G C T G C C C T A T C C A T 
T C T C C C T C C T A C A C A G C C A A G A T T C T T A A A A A A C C A A 
T C C A A A T T T G C A G A A T C T C C G 
100422876 
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A web-based tool, miRNA sponge generator and tester (miRNAsong, 
http://www.med.muni.cz/histology/miRNAsong) was used to produce the sponge sequences 
for each miRNA (Barta et al., 2016). Table 2 shows the criteria used to produce the sequence 
for each miRNA sponge. 
 
Table 2 The miRNA sponge sequence constructs that were purchased  
miRNAsong was used to make miRNA sponges specific to each miRNA to reduce the levels of miRNA in the 
calcification model. 
Sponge Sequence Criteria Sponge Sequence 
The miR-30d-5p sponge sequence included 3 miRNA-
binding sites (MBS), a bulge at nucleotide position 11-14, 
and a spacer sequence AAAAU between individual MBSs. 
Test for off-targets showed that the generated sequence 
binds to miR-30a-5p and miR-30e-5p as well as miR-30d-
5p (free energy -86.4 kcal/mol) (settings: -25 kcal/mol cut 
off and canonical 6-mer seed). 
C T T C C A G T A T T G A T G T T T A C A A A A 
A T C T T C C A G T A T T G A T G T T T A C A A 
A A A T C T T C C A G T A T T G A T G T T T A C 
A  
The miR-320a sponge sequence included 3 miRNA-binding 
sites (MBS), no bulge, and a spacer sequence AAAAAA 
between individual MBSs. Test for off-targets showed that 
the generated sequence binds only to 39 other miRs as 
well as miR-320a (free energy -146 kcal/mol) (settings: -
25kcal/mol cut off and canonical 6-mer seed). 
T C G C C C T C T C A A C C C A G C T T T T A A 
A A A A T C G C C C T C T C A A C C C A G C T T 
T T A A A A A A T C G C C C T C T C A A C C C A 
G C T T T T  
The miR-3148 sponge sequence included 3 miRNA-binding 
sites (MBS), no bulge, and a spacer sequence UAAA 
between individual MBSs. Test for off-targets showed that 
the generated sequence binds only miR-3148 (free energy 
-125.7 kcal/mol) (settings: -25kcal/mol cut off and 
canonical 6-mer seed). 
A A G C A C A C A C C A G T T T T T T C C A T A 
A A A A G C A C A C A C C A G T T T T T T C C A 
T A A A A A G C A C A C A C C A G T T T T T T C 
C A  
 
 
All constructs were produced to include sites for HpaI [G T T A A C] attB1 [C A A G T T T G T A 
C A A A A A A G C A G G C T], attB2 [A C C C A G C T T T C T T G T A C A A A G T G G T] and XhoI 
[C T C G A G], in the following order: HpaI – attB1 – target DNA – attB2 – XhoI. The HpaI and 
XhoI sites were included for the purpose of cloning by restriction enzyme digest and ligation 
19 
 
with lentiviral vector, pLL3.7, and the attB sites were included for later use in production of a 
DV by a BP recombination reaction as a part of the Gateway® Cloning Technology (Invitrogen). 
800 ng of plasmid constructs containing the DNA sequence for the miRNAs and their respective 
sponges, and the lentiviral vector pLL3.7 (shown in Figure 3) (Rubinson et al., 2003) were 
digested using restriction enzymes for HpaI (1 µl) (NED, R0746S) and XhoI (1 µl ) (NEB, R0105S), 
using 10x cut smart buffer (3 µl ) (NEB, B7204S) in analytical grade water (to make up 30 µl 
final volume). pLL3.7 is a third-generation lentiviral vector containing the green fluorescent 
protein (GFP) reporter gene. 
 
 
Figure 3 Full sequence map for pLL3.7 vector. (Source: Addgene, Plasmid#11795) 
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1% Agarose (Invitrogen, 165000-100) gel made in 1x TAE buffer was used for electrophoresis, 
using Midori Green (Nippon, MG04) to stain the DNA strands. 30 µl of each plasmid sample 
was loaded into the wells and electrophoresis conducted at 120 V for 30 minutes. LI-COR Image 
Studio software was used to capture all electrophoresis images in this study (Figure 4). The gel 
was incubated in 0.1 µl/ml of SYBR™ Gold (Invitrogen, S11494) in 1x TAE buffer, on a rocker at 
RT for 30 minutes. Bands were observed under an Ultraviolet light (UV) transilluminator and 
the target fragments excised using a scalpel before isolating the DNA using Zymoclean™ Gel 
DNA Recovery Kit (Zymo Research), eluting in 10 µl DNA elution buffer (Demeke et al., 2009). 
The DNA was stored at -80°C until further use. 
 
 
Figure 4 Electrophoresis of digest of commercially produced DNA constructs 
Electrophoresis was carried out at 120V for 30 minutes. (A) The images show bands for the restriction enzyme digests of 
miRNA-30d-5p (329 bp), miRNA-320a (341 bp) and miRNA-3148 (330 bp) constructs. (B) Restriction digests of the sponges for 
miRNA-30d-5p (132 bp), miRNA-320a (131 bp) and miRNA-3148 (133 bp) constructs. (C) Restriction enzyme digest of PLL 3.7 
shows only one band at 7650bp. Red arrows indicate presence of bands. 
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A Qubit™ dsDNA HS Assay Kit (Invitrogen, Q32854) and Qubit™ 4 Fluorometer was used to 
determine the concentration of DNA recovered (Mardis and McCombie, 2017). The amount of 
insert DNA (miRNA or miRNA sponge DNA) required for ligation (with lentiviral vector pLL3.7) 
was then calculated using the equation 
amount of vector (ng) 𝑥 𝑟𝑎𝑡𝑖𝑜 𝑥 𝑖𝑛𝑠𝑒𝑟𝑡 𝑠𝑖𝑧𝑒 (𝑏𝑝)
vector size (bp)
, where the 
amount of vector was 30.4 ng and the vector size was 7650 bp. Ligation was carried out with 
a vector to insert ratio of 1:5, using 10 µl of 2 x Quick Ligase Reaction Buffer (BioLabs, B2200S), 
30.4 ng vector, 1 µl Quick Ligase (BioLabs, M2200L), and analytical grade water to make up a 
final volume of 20 µl, followed by incubation at RT for 10 minutes. 
The ligation reactions (5 µl per reaction) were transformed into One Shot™ Stbl3™ chemically 
competent E. Coli cells (Invitrogen, C737303) according to the manufacturer's instructions, 
followed by addition of RT S.O.C. Medium (250 µl) (Invitrogen, 15544-034).  The cells were 
placed horizontally in an incubator with a shaker at 37°C for 1 hour (80 rpm), followed by 
pouring onto individual pre-warmed selective plates (3.2%, LB Lennox L agarose gel, 
Invitrogen, 00602061) with 25 µg/ml ampicillin, using aseptic techniques. The plates were 
inverted and incubated at 37°C overnight. 
Individual colonies were selected from each plate and cultured in 5 ml 2% LB broth base 
solution (Lennox L broth, Invitrogen, 00602271), supplemented with 25 µg/ml ampicillin, and 
incubated overnight at 37°C on a shaker. Glycerol stocks of each culture were produced (50%, 
Fisher Scientific, BP229-1) and stored at -20°C. Plasmids from the remaining bacterial solution 
were extracted using QIAprep Spin Miniprep Kit. DNA concentration and purity was measured 
by UV absorbance at 260 and 280 nm using a NanoDrop™ spectrophotometer (A260/280 ratio 
of approximately 1.8). DNA integrity was determined by digesting 800 ng of DNA using 
restriction enzymes XhoI and HpaI, followed by electrophoresis of the samples (Figure 5). 
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Figure 5 Electrophoresis of digested clones of miRNA and their sponges from the mini prep 
Electrophoresis was carried out at 120V for 30 minutes. Bands in the images show presence of the insert DNA sequences: 
miRNA-30d-5p (329 bp), miRNA-320a (341 bp), miRNA-3148 (330 bp), miRNA-30d-5p sponge (132 bp), miRNA-320a sponge 
(131 bp) and miRNA-3148 sponge (133 bp). Red arrows indicate presence of bands of the expected sizes. 
 
Plasmids and transfer vector were further amplified from 20 µl of the glycerol stocks, cultured 
in 20 ml 2% broth base solution (supplemented with 25 µg/ml ampicillin). DNA was purified 
using Plasmid Midi Kit (Qiagen, 12143) according to the manufacturer’s instructions. 
Electrophoresis was performed at 120V for 30 minutes to determine DNA integrity (Figure 6). 
 
 
Figure 6 Electrophoresis of digested clones of miRNA and their sponges from the midi prep  
Electrophoresis was carried out at 120V for 30 minutes in 1% agarose gel. The bands represent the insert DNA sequences: 
miRNA-30d-5p (329 bp), miRNA-320a (341 bp), miRNA-3148 (330 bp), miRNA-30d-5p sponge (132 bp), miRNA-320a sponge 
(131 bp) and miRNA-3148 sponge (133 bp). Red arrows indicate presence of bands. 
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2.5 Overexpression and Depletion of miRNAs in Cultured Human CASMCs 
Due to the high transfectability and adaptability of HEK 293 cells, they are extensively used for 
lentiviral vector production (Segura et al., 2007), with the variant 293T being efficient in high-
titre lentiviral production (Tiscornia et al., 2006). The enveloped protein plasmid pMD.G2 that 
codes for the vesicular stomatitis virus (VSV-G) envelope glycoprotein and the third-generation 
packaging plasmid pCMV-dR8.91 (Delta 8.9, containing HIV gag/pol/rev coding sequences) 
provided the helper functions for lentivirus production. 
293T cells were seeded overnight in T175 flasks (60-70% confluency) and transfected using 
target DNA, pMD.G2 and pCMV-dR8.91, at a ratio of 3:1:1, respectively. Plasmids were pre-
complexed with 7mM Polyethylenimine reagent (PEI, Polysciences) diluted in 150 mM NaCl. 
Transfection complexes (DNA-PEI) were prepared by adding 1 ml PEI mixture to plasmid DNA 
diluted in 150 mM NaCl (to form a final volume of 1 ml). The mixture was vortexed and 
incubated at RT for 10 minutes before adding to the cultured cells. At 24 hours the media was 
discarded and replaced. All viruses were harvested at 48 and 72 hours by centrifugation at 
2000 x g for 10 minutes and the supernatant collected, filter sterilised (0.22 µM) and stored at 
-80°C. 
CASMCs were plated in 6-well plates in SMC growth medium 24 hours prior to infection, at a 
cell density of 1.2 x 106 per well. 500 µl supernatant was added per well with 1.5 ml DMEM. 
GFP gene expression was visualised using fluorescent microscopy. 
2.6 RNA Extraction and qRT-PCR 
To test for primer efficiency, RNA from 293T cells and CASMCs, in DMEM only, was extracted 
using the Bioline Isolate II RNA mini kit (Ambion, 15596026) according to the manufacturer’s 
instructions, and concentration was determined using NanoDrop Spectrophotometer at an 
A260/A280 absorbance ratio of approximately 2.0. For reverse transcription, 2 µg of RNA was 
used to produce cDNA with the Tetro cDNA Synthesis Kit (Bioline, BIO-654043), using random 
hexomers, as per the manufacturer’s instructions. Efficacy of primers were tested in triplicate 
using SensiFAST SYBR Lo-ROX Mix, 2x (Bioline, BIO-94005), and real time q-PCR was run, over 
three 10-fold serial dilutions as follows: 95°C for 5 seconds, 62°C for 10 seconds and 72°C for 
18 seconds, for 40 cycles. Primer efficiency was calculated using the equation 𝐸 = 10
(
−1
𝑠𝑙𝑜𝑝𝑒
)
−
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1, using the mean CT value for each dilution. Primers with amplification efficiencies ranging 
from 90% to 110% were used. The melting curve for each primer was also observed (Figure 7). 
The primers used for the current research study are summarised in   
 
 
 
 
Table 3. 
 
 
Figure 7 Melt curve for Sirt1 primers 
This melt curve is produced from 3 different dilutions of the primers in the same RNA sample from 293T cells (passage 5) 
grown in high glucose DMEM.  
 
For gene analysis, RNA from CASMCs were isolated on day 4 of treatment with osteogenic 
media. The expression of target genes were normalised to the expression of GAPDH and 
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expression levels of the genes were calculated with the comparative cycle threshold (CT) 
method.  
 
 
 
 
Table 3 Primers used in this research 
Primers were designed using NCBI/Primer-BLAST (Ye et al., 2012) with the following conditions: 58 to 62°C melting 
temperature, maximum intron length 300, primers must span exon-exon junction. 
Primer Name Primer Sequence (5’ to 3’) 
MMP16 Forward: T G C G G A A C G G A G C A G T A T T T 
Reverse: G G G G C T T C T T C A T C C A G T C A A T 
SOX9 Forward: G C T C T G G A G A C T T C T G A A C G A  
Reverse: C C G T T C T T C A C C G A C T T C C T 
SIRT1 Forward: A G G C C A C G G A T A C G T C C A T A 
Reverse: G T G G A G G T A T T G T T T C C G G C 
BMP2 Forward: G G A A C G G A C A T T C G G T C C T T 
Reverse: C A C C A T G G T C G A C C T T T A G G A 
RUNX2 Forward: G A G G G C A C A A G T T C T A T C T G 
Reverse: C G C T C C G G C C C A C A A A T C T C 
GAPDH Forward: C C A C C C A T G G C A A A T T C C A T G 
Reverse: T C T A G A C G G C A G G T C A G G T C C A C C 
 
 
2.7 Alkaline Phosphatase Activity Assay 
The enzyme alkaline phosphatase is a well-established early marker of osteogenic 
differentiation of SMCs and was used in this study to assess effects on the process following 
treatment with miRs. CASMCs were lysed at day 4 and day 7 with 0.05% Triton X-100 (200 
µl/well) after washing with PBS thrice and freeze-thawed twice. The suspension was 
centrifuged at 12,000 x g for 10 minutes and the supernatants collected. Pierce BCA™ Protein 
Assay (ThermoFisher Scientific, 23227) was performed and the protein standard curve 
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produced was used to determine sample protein concentration. For the Alkaline Phosphate 
(ALP) activity assay, 1 mM p-Nitrophenol (Sigma-Aldrich, N7660) was diluted using 0.05% 
Triton to produce standards of different concentration. Standards and 20 µl of extracted 
protein were loaded in triplicates into a 96-well plate followed by addition of p-Nitrophenyl 
phosphate substrate system (180 µl/well, Sigma-Aldrich, N7653). After incubation at 37°C for 
30 minutes, activity was measured spectrophotometrically at 405nm and calculated using the 
standard curve, as nM p-nitrophenol converted/ug protein for each lysate sample. 
2.8 Protein Extraction, and Western Blot Analysis 
To extract protein from CASMCs in osteogenic media at day 4, cells were treated with 30 µl 
RIPA lysis buffer containing 1% Phosphatase Inhibitor (Sigma-Aldrich, P5726) and 1% Protease 
Inhibitor (Sigma-Aldrich, P8340). The suspension was incubated on ice for 20 minutes, with 
vortexing every 2 minutes, followed by centrifugation for 4 minutes at 21,130 x g, at 4°C. The 
supernatant was removed and BCA™ protein assay kit was used to quantify protein. Loading 
dye (NuPAGE, Thermofisher Scientific, NP0008) was added to 15 µg protein to make up 25 µl 
and the proteins were electrophoresed on 4-12% Bis-Tris Gel (Invitrogen, NuPAGE™, 
NP0321PK2) for 2 hours at 120 V using 1x Running Buffer (Thermo Fisher Scientific, NP000102) 
after denaturing at 99°C for 2 minutes. The proteins were then electrotransferred to a P 0.45 
PVDF Blotting Membrane (GE Healthcare Life sciences, Amersham™ Hybond™, 10600023) over 
1 hour at 35V using Transfer Buffer (Thermo Fisher Scientific, NP00061). The membrane was 
blocked for 1 hour in blocking buffer (5% milk in 0.05% PBS-Tween). The membrane was 
probed in blocking buffer with anti-Runx2 antibody (dilution 1:1000, Abcam, AB76956), with 
anti-α-tubulin (dilution 1:5000, Abcam, AB7291) used as a loading control, overnight, at 4°C, 
followed by washing with 0.1% PBS-Tween and incubation with corresponding horse radish 
peroxidase-labelled secondary antibodies (dilution 1:2000) for 1 hour at RT. Secondary anti-
mouse antibody (Sigma Aldrich, A9044) was used for both Runx2 (57 kDa) and α-tubulin (50 
kDa). After washing with PBS-tween, Western ECL substrate (Millipore Immobilon® Western, 
WBK150500) was added to the membranes and images captured. 
2.9 Gateway® Cloning Technology 
Using the previously produced lentiviral backbone Expression Clone with commercially 
produced DNA, expressing genes HpaI – attB1 – target gene – attB2 – XhoI and ampicillin 
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resistance, a lentiviral backbone DV with HpaI – attB1 – chloramphenicol resistance (CMR) – 
attB2 – XhoI and ampicillin resistance sites was created via the BP recombination reaction. 
pDONR™221 (plasmid map displayed in Figure 8) (Invitrogen, 12536017) was digested with the 
following restriction enzymes; EcoRV-HF (NEB, R3195S), NSiI-HF (NEB, R3127S) and HpaI, 
diluted in cut smart buffer and analytical grade water. After incubation at 37°C for 2 hours, the 
digest was electrophoresed (Figure 9) and target DNA fragment (2.5 kb) excised followed by 
DNA isolation from the gel. Figure 10 outlines schematically the reaction taken place to 
produce the destination vector. 
 
 
Figure 8 Full sequence map of donor vector pDONR™221 (Source: Snapgene, pDONR™221) 
pDONR™221 contains the gene for ccdB and Chloramphenical resistance (CMR) to allow for negative selection of the 
Destination Vector. 
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Figure 9 Electrophoresis of digested pDONR™221  
pDONR™221 vector was digested with restriction enzymes HpaI (501 bp), EcoRV (2999 bp) and NSiI (3431 bp and 3697 bp). 
The digest was electrophoresed using 1% agarose gel for 40 minutes at 120V. The band at 2498 bp represents the target DNA 
containing the following sites; attP1 – ccdB – CMR – attP, and the band at 1566 bp (A), 432 bp and 266 bp (B) were discarded. 
The bands were observed under a UK transilluminator for excision (C) ccdB =  Toxin CcdB gene, CMR = Chloramphenicol 
resistance. The red arrow indicates target DNA. 
 
 
Figure 10 A diagram to represent the BP recombination reaction to produce 
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Recombination occurs between the attachment (att) sites of the Expression Clone and donor vector in the presence of BP 
Clonase™ Enzyme mix. Recombination between attB (25 bp) and attP (200 bp) sites produce attL (100 bp) and attR (125 p) 
sites. AMPR = Ampicillin resistance, CMR = Chloramphenicol resistance, KANR = Kanamycin resistance.  
 
2.10 Sequencing of DNA 
DNA integrity was checked by sequencing each of the DNA fragments used in this project 
miRNA-30d-5p, miRNA-320a, miRNA-3148, sponges for each of the miRNAs and the DV 
produced by the BP recombination reaction. For this sequencing, the following primer was 
used: 5’A G G A A A C T C A C C C T A A C T G T A A A G. 1 µl of the primer (40 µM) was mixed 
with 300 ng of each DNA in separate tubes and analytical grade water added to make a final 
volume of 10 µl. These mixtures were outsourced for sequencing by a collaborative team at 
the Manchester Regenerative Medicine Network (MaRM) at the University of Manchester.  
2.11 Statistical Analysis 
Data were found to be not normally distributed according to D’Agostino & Pearson omnibus 
normality test and were compared using one-way analysis of variance (ANOVA) Kruskal-Wallis 
test followed by Dunn’s corrections. GraphPhad Prism, version 5.04, was used to analyse data. 
Mean and standard deviation were calculated based on three or more measurements and 
presented as a mean ± standard error mean (SEM). A probability (P) value of less than 0.05 
was considered as statistically significant. 
3 Results 
3.1 miR-3148 Levels Increase under Inflammatory Conditions 
Following the miR expression profiling in serum from patients with SLE using computational 
tools, the next series of experiments focused on some of the miRs that were elevated in this 
patient group, namely miR-3148, -30d-5p and 320a. In order to generate an in vitro 
inflammatory model, that would reflect conditions within the SLE patient group, we used the 
standard model that has been described previously in this group where SMCs were treated 
with the inflammatory cytokine TNF- α (Parker et al., 2014; McCarthy et al, 2017). The level of 
miR-3148 was determined in cells and microvesicles isolated from the media aspirated from 
control (exosome-free DMEM only) and TNF-α-treated cells, by qRT-PCR. This treatment 
reflects the elevated inflammatory conditions experienced in the vasculature of SLE patients 
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and allows investigation of the level of miR-3148 in the cells and microvesicles in the 
extracellular matrix in vitro. There was a higher level of miR-3148 expression in cells and 
microvesicles from the media of cells treated with TNF-α compared to control (Figure 11). 
 
 
Figure 11 miR-3148 mRNA expression under inflammatory conditions 
CASMCs were serum starved for 24 hours before treating with TNF-α in exosome-free DMEM for 24 hours. Microvesicles were 
isolated by ultracentrifugation and miRNA extracted from cells and microvesicles as previously described by our group 
(McCarthy et al., 2016; Mahmoud et al., 2017). qRT-PCR was carried out to observe the expression of mRNA for miR-3148 
where the control was treated with exosome-free DMEM only. The level of miR-3148 expression was higher in cells and 
microvesicles from media treated with TNF-α compared to control. The data are expressed as densitometric ratios of miR-
3148/let-7a-5p. (n = 1) 
 
3.2 High Titre Lentiviral Vectors show a stable expression 
pLL3.7, a third-generation lentiviral vector, contains the GFP reporter gene and its expression 
can be visualised under fluorescence microscopy where the cells that have been transfected 
express the GFP reporter gene. Weekly examination of GFP expression revealed a stable 
expression over the calcification assay period of 15 - 18 days, as shown in Figure 12. A one-way 
ANOVA test showed an increase in the percentage of transfected cells (68.8 ± 1.47% at 72 
hours, 88.1 ± 0.90% at day 7 - 9 and 97.0 ± 0.5% at day 15 - 17, P = 0.0001). 
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Figure 12 Third-generation lentivirus efficiently transduce CASMCs 
GFP expression (green) visualised under a live-cell imaging fluorescent microscope at 72 hours without lentiviral vector (A) 
and 72 hours (68.8 ± 1.47%) (B), day 7 - 9 (88.1 ± 0.90%) (C) and day 15 - 17 (97.0 ± 0.5%) (D) after transfecting CASMCs with 
miRNA-3148 lentivirus. Transfection of cells was quantified by counting cells infected with the lentivirus (green) and total 
number of cells in the image, for each of the miRNA and their respective sponges, and pLL3.7 vector (E). A two-way analysis 
of variance (2-way ANOVA) shows an increase in the percentage of transfected cells with time (P = 0.0001). Data are 
representative images of each group of cells and data is expressed as mean ± S.E.M. (n = 4) 
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3.3 Effect of miRNA-30d-5p and -320a on calcification of coronary artery 
smooth muscle cells 
Cells were transfected with miR-30d-5p and 320a (Figure 13A & C) and their respective sponge 
controls (Figure 13B & D) respectively. An empty control viral vector pLL3.7 was used as 
transfection control (Figure 13E). All cells were cultured in osteogenic media containing high 
calcium (2.6 mmol/L) and βGP (5 mmol/L). The empty vector control cells deposited a 
mineralised matrix at day 18, which stained positive (red) with ARS and being the highest level 
of mineralisation taken as 100% (Figure 13E). Cells transfected with miR-30d-5p and -320a 
appeared to decrease mineralisation vs empty vector control (Figure 13A, C & F) (68.6 ± 7.15% 
and 52.4 ± 6.5% respectively). However, the respective sponge controls (Figure 13B, D & F) also 
produced less mineralisation compared to the empty control vector (61.6 ± 7.5% and 47.2 ± 
6.5% respectively), but no significant difference to their respective miR mimicas (Figure 13F). 
The levels of Alizarin Red staining was quantified and summarised in Figure 13F. 
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Figure 13 ARS staining of CASMC growth in osteogenic media 
Mineralisation from the empty vector was taken as 100% and the test miRNAs were expression as a % relative to this. CASMCs 
transduced with miR-30d-5p (A); miR-30d-5p sponge (B); miR-320a (C); miR-320a sponge (D); and control empty pLL3.7 vector 
(E) were stained at day 15 – 18 of treatment. ARS staining of calcified CASMCs was quantified via elution with 10% Formic acid 
and measured spectrophotometrically at 414 nm (F). Data are representative images of each group of cells and data is 
expressed as mean ± S.E.M. (n = 2), and the value of the control cells were designated as 100%. 
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3.4 Overexpression of miRNA-3148 affects calcification in vitro 
Confluent CASMCs were transfected with either empty pLL3.7 vector, miR-3148 lentivirus or 
miR-3148 sponge vector and cultured in osteogenic media to induce mineralisation. A one-way 
ANOVA test indicated an apparent lower calcific matrix formation in cells transfected with miR-
3148 compared to control, empty pLL3.7 lentiviral vector, by quantification of ARS staining 
(73.4 ± 8.1% and 100%, respectively, P = 0.0201) (Figure 14A, C & D). Fold change amounted 
to 79.5 ± 11.4% for miR-3148 sponge (Figure 14 B & D). 
 
 
Figure 14 miR-3148 reduces calcific matrix formation 
CASMCs transduced with miR-3148 (A); miR-3148 Sponge (B); and control empty pLL3.7 vector (100%) (C) was stained with 
ARS at day 18 of treatment. ARS staining of calcified CASMCs were quantified via elution with 10% Formic acid and measured 
spectrophotometrically at 414nm (D). Data are representative images of each group of cells and data is expressed as mean ± 
S.E.M. (n = 4), and the value of the control cells were designated at 100%. * = significant difference (P = 0.0201), ns = no 
significant difference 
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35 
 
3.5 miR-3148 Reduces Runx2 Gene Expression 
In order to identify the pathways through which miR-3148 was executing its effects, the next 
series of experiments was carried out to determine whether this transcription factor was in 
fact targeted by miR-3148. Among the many Runx2-targeting miRNAs, miR-3148 has been 
suggested as a potential modulator of VC via regulation of Runx2 expression. At day 4, CASMCs 
in osteogenic media transfected with miR-3148 showed lower expression of Runx2 compared 
to the control (0.061 ± 0.030 fold change vs 0.238 ± 0.157 fold change) and compared to miR-
3148 sponge (0.171 ± 0.122 fold change). Although there was a trend towards reduction in 
Runx2 mRNA abundance in cells transfected with miR-3148 viral vector, the difference was not 
significant. Runx2 expression was lower in cells transfected with the miR-3148 sponge 
compared to control (Figure 15).  
 
 
Figure 15 miR-3148 negatively regulates calcific matrix formation 
qRT-PCR was conducted on RNA extracted from CASMCs at day 4 of the calcification assay. Expression of Runx2 mRNA in 
pLL3.7, miR-3148 and miR-3148 sponge lentivirus transfected cells, relative to GAPDH expression, is shown. Data are 
expressed as mean ± S.E.M. (n = 4), and the values of the control gene, GAPDH, expression were designated as 1. Significant 
difference was not observed between the different treatments.  
 
Western blot analysis was conducted to investigate the expression of the Runx2 protein at day 
4 in cells cultured in osteogenic media. It is difficult to draw a conclusion from the results for 
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Runx2 protein stain (Figure 16) as there was no evidence of the presence of Runx2 protein. 
The loading control, α-tubulin, was present in all protein samples. The reason for the lack of 
detectable expression is unclear, but maybe a later time-point in the mineralisation process 
will yield a different result. 
 
 
Figure 16 Protein level at day 4 
Total protein cell extracts (15 µg) of CASMCs were electrophoresed using 4-12% Bis-Tris gel. Western blotting was performed 
by probing with purified anti-Runx2 (57 kDa), with an anti-α-tubulin (50 kDa) antibody being used as loading control. (n = 1) 
 
3.6 Changes in ALP activity 
In support of previous findings using ALP activity as an early marker of osteogenic 
differentiation, a small increase was observed at day 4 in cells from all treatments (pLL3.7 
0.000199 ± 0.0.00379 nmol/L; miR-3148 0.00108 ± 0.00391 nmol/L; miR-3148 sponge 0.00086 
± 0.0.00525 nmol/L), with the highest increase in cells transfected with miR-3148 lentivirus. At 
day 7, a small increase in ALP activity in control cells and a comparatively higher increase in 
cells with elevated levels of miR-3148 (0.00049 ± 0.00366 nmol/L and 0.00358 ± 0.00394 
nmol/L respectively) was observed. There was a drop in ALP activity in cells transfected with 
miR-3148 sponge (-0.00077 ± 0.00387 nmol/L) as shown in Figure 17. 
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miR-3148 
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Figure 17 ALP activity of cells cultured in osteogenic media 
CASMCs were seeded in 6-well plates and transfected with lentiviral vectors in osteogenic media. Protein was isolated and 
quantified using BCA assay and then ALP activity assay performed. Absorbance of protein solutions from each well was 
measured at 405nm. (n = 1) 
 
3.7 Altered expression of calcification-related genes 
Figure 18 displays the level of gene expression of the chosen calcification-related genes under 
the various conditions. BMP2 is a predicted target for miR-3148, however, the expression of 
BMP2 is higher in cells transfected with miR-3148 (0.00256 ± 0.00216 fold change) than control 
(0.00085 ± 0.00066 fold change) and less than in cells transfected with miR-3148 sponge 
(0.00505 ± 0.00476 fold change). Sirt1 gene expression was lowest in cells transfected with 
miR-3148 compared to the control and sponge. Sirt1 gene expression analysis amounted to 
0.00493 ± 0.00231-fold change, 0.00303 ± 0.00167-fold change and 0.00687 ± 0.00203-fold 
change for cells transfected with empty pLL3.7, miR-3148 and miR-3148 sponge, respectively. 
Highest level of Sox9 expression was observed in cells transfected with miR-3148. Sox9 gene 
expression analysis amounted to 0.00045 ± 0.00027-fold change, 0.001229 ± 0.00059-fold 
change and 0.00094 ± 0.000281-fold change for control, miR-3148 and miR-3148 sponge 
transfected cells, respectively. Levels of MMP16 (Matrix metalloproteinases 16) was highest in 
miR-3148 transfected cells. The MMP16 gene expression levels amounted to 0.00268 ± 
0.00138-fold change, 0.00845 ± 0.00466-fold change and 0.00472 ± 0.00359-fold change for 
cells transfected with control, miR-3148 and miR-3148 sponge vectors, respectively. These 
data show no clear trend for BMP2 expression, a trend towards reduction of Sirt1 in cells with 
elevated miR-3148 levels, and a trend towards elevation of Sox9 and MMP16 in these cells, 
however, no significant changed was detected. 
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Figure 18 Gene expression in CASMCs at day 4 
(A-D) CASMCs were transfected with control empty lentiviral vector pLL3.7 or miR-3148 or miR-3148 sponge and subjected to 
qRT-PCR analysis of BMP2 (A), Sirt1 (B), Sox9 (C) and MMP16 (D). Data is expressed as a relative fold change compared with 
GAPDH mRNA. The data are expressed as mean ± S.E.M. of each group of cells from three separate experiments, and the 
values of the control gene, GAPDH, expression were designated as 1. Significant difference was not observed between any of 
the conditions for each of the genes. (n = 3) 
 
3.8 Destination Vector for Gateway® Cloning  
The DV produced via the BP reaction using Gateway® Cloning technology was extracted from 
transformed bacteria and analysis of recombinant clones was carried out by investigating the 
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integrity of the DNA which was established by restriction enzyme digestion and 
electrophoresis (Figure 19). The presence of a band at 2.7 kb (length of the Gateway® cassette 
containing attR1, ccdB, chloramphenicol resistance and attR2 genes) confirmed successful 
selection and amplification of the DV. 
 
 
Figure 19 Electrophoresis of digested destination vector  
Electrophoresis was carried out at 120V for 15 minutes. The lower 2.1kb band in the right column represents the Gateway® 
cassette sequence containing attR1, ccdB, CMR and attR2 sites. 
 
3.9 Confirmation of Successful Vector Contruction by DNA Sequencing  
DNA sequencing was conducted on all vectors containing miRNA and their respective sponges, 
and the DV produced via BP reaction. Sequencing the vector DNA showed successful 
amplification of each vector. Figure 20 shows the sequencing results of the Gateway® cassette 
in the DV. 
 
Figure 20 Sequencing of destination vector  
Sequencing showed the presence of attR1 site in the Destination Vector produced via the BP reaction using enzyme BP 
Clonase™. 
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4 Discussion 
Recent studies have supported the finding that young women with SLE have a high risk of 
developing atherosclerosis and subsequent vascular calcification compared to their healthy 
counterparts, and the severity of the calcification determines cardiovascular mortality and 
morbidity (Manzi et al., 1997). The aetiology of accelerated coronary artery calcification in 
these patients is multifactorial, but the precise mechanism underlying the osteogenic 
differentiation of CASMCs in this patient group remains unclear. Studies from our group have 
previously shown an increase in the levels of endothelial cell-derived microvesicles in SLE 
patients and changes in levels of a range of miRNAs compared to control patients (Edwards et 
al., 2018). Numerous studies have shown a crucial role of miRNAs in modulating CVD. For 
example, increased miR-133a, -125b and -204 activity inhibit osteoblastic differentiation of 
VSMCs by targeting Runx2 expression, whereas suppression of activity of these miRNAs induce 
VSMC osteoblastic differentiation (Goettsch et al., 2011; Cui et al., 2012; Liao et al., 2013). 
Wang and colleagues (2015) have confirmed the inhibitory effects of miR-204 on the 
transdifferentiation of human aortic vascular interstitial cells into osteoblast-like cells by 
targeting Runx2. 
TNF-α is a potent inflammatory factor and an immunoregulatory cytokine involved in the 
pathological basis of endothelial injury and atherosclerosis (López-Pedrera et al., 2010; Zhang 
et al., 2014). Under inflammatory conditions in the vasculature, TNF-α is primarily released by 
monocytes and macrophages (Tintut et al., 2000; Durham et al., 2018). In cultured human 
CASMCs, the addition of TNF-α stimulated production of miR-3148 within the cells and in 
microvesicles released from the cells. These results correlate with the increase in miR-3148 in 
the peripheral blood of patients with SLE as shown by preliminary data generated by our group. 
Complementary studies, carried out in our group by Dr Alex Langford-Smith and Nicola 
Edwards, show significantly elevated levels of miR-3148 in microvesicles isolated from SLE 
patients (n = 26) compared to controls (n = 14), P = 0.001 (unpublished data). Furthermore, 
many studies have revealed an increase in release of EMVs from activated endothelial cells 
and cultured human umbilical vein endothelial cells in response to TNF-α (Buendía et al., 2015; 
McCarthy et al., 2016), suggesting the source of EMVs and miR-3148 may be endothelial cells 
in addition to CASMCs. Work by Tintut et al. (2000) demonstrated an upregulation of Runx2 
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expression in response to stimulation by TNF-α in in vitro studies on calcification of bovine 
VSMC cultures. 
In the present study, to investigate the role of miR-30d-5p, -320a and -3148, human CASMCs 
were transduced with third-generation lentivirus containing synthetic miRNA mimics or 
sponges for altered miRNA activity, in an in vitro model of calcification. To decrease the level 
of miRNA, miRNA sponges were produced and introduced to the cells using lentivirus. 
Lentiviral vectors were producing using three vectors; (a) a third-generation packaging plasmid 
pCMV-dR8.91 coding for vital components of the virion, derived from HIV-1; (b) an enveloped 
protein plasmid that codes for VSV-G, due to its broad tropism and high stability (Klages et al., 
2000) and (c) pLL3.7 plasmid encoding the target gene. The third-generation packaging plasmid 
used contains three genes of HIV-1: gag, codes for the core structural proteins of the virion; 
pol, encodes retrovirus-specific enzymes; and rev, codes for a post-transcriptional regulator 
required for gag and pol expression (Klages et al., 2000). 
The changes caused by transfecting cells to alter miRNA levels were observed in an in vitro 
calcification assay model using ARS staining and quantification methods, followed by 
determining the expression of genes associated with calcification. The process of calcification 
under pathological conditions occurs over decades, so an in vitro model to mimic this process 
was generated using high glucose DMEM supplemented with 2.6 mmol/L CaCl2 and 5 mmol/L 
βGP, for 15 to 18 days, depending on the experiment. This is the first study to assess the role 
of miRs in the pathology of calcification, which many be associated with the pathology of SLE. 
Although n numbers were small and did not allow statistical analysis to be calculated, the data 
generated suggest that the miR-3148 inhibits CAC in CASMCs cultured in osteogenic media in 
vitro. There was a lower level of mineralisation in cells transfected with miR-3148 lentivirus 
compared to control (empty pLL3.7 vector). This correlates with the trend towards a decrease 
in expression of Runx2 gene in these cells at day 4, under the same condition. Runx2 is a 
transcription factor which encodes a nuclear protein which is essential for osteogenic 
differentiation of cells and skeletal morphogenesis via multiple pathways. In VSMCS, Runx2 is 
able to regulate expression of VSMC marker genes under oxidative stress, including myocardin 
and serum response factor (SRF), a transcription factor crucial in modulating cell growth and 
differentiation (Sun et al., 2012; C. Chen et al., 2015; Frismantiene et al., 2018). The 
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upregulation of Runx2 may disturb the formation of SRF/myocardin complexes and participate 
in the decreased expression of SMC gene markers (Sun et al., 2012). Consequently, Runx2-
deficient VSMCs have normal expression of SMC markers, allowing the cells to perform their 
normal functions under healthy physiological conditions. In addition, under normal conditions 
the vasculature expresses mineralisation inhibitors such as feutin-A and matrix Gla protein 
(MGP) which abrogates mineralisation (Reynolds et al., 2004). Expression of bone 
mineralisation and matrix proteins are also regulated by Runx2 (Zamurovic et al., 2004). The 
phenotypic changes in the cells under disease conditions allow them to express calcification-
regulating proteins that are normally confined to bone and cartilage (Shanahan et al., 1999). 
Moreover, Runx2 is known to affect the expression of different miRNAs, for example, it is able 
to bind to the promoter regions of miR-23a, -27a and -24-2 cluster involved in mineralisation, 
limiting their expression (Hassan et al., 2010). This illustrates the complex system of miRNA 
gene regulation.  
miRNA targets and target prediction scores were identified using DIANA-TarBase algorithms 
(Vlachos et al., 2015). miR-3148 targets Runx2 (target prediction score: 0.9988), and therefore, 
downregulates Runx2 expression, leading to reduced secretion of osteocalcin and osteopontin 
among other factors supporting calcification (Zamurovic et al., 2004), followed by a reduced 
CASMC differentiation into osteogenic-like cells and consequential decrease in mineralisation. 
These data support the findings of Sun et al. (2012) where evidence was reported of osteogenic 
differentiation of VSMCs contributing to vascular calcification, and the importance of Runx2 
expression within VSMCs in regulating the calcification process. During development, Runx2 
expression precedes differentiation of cells by several days, hence why gene expression was 
analysed at day 4. Changes in Runx2 protein expression under the different lentiviral vectors 
was also examined, but Runx2 proteins were not observed in the Western blot analysis which 
may be due to the anti-Runx2 antibody which was used, or the possibility that the protein was 
in too low abundance to be detected. In the interest of time, Western blot optimisation was 
not carried out in this case. The presence of bands in the control stain for protein α-tubulin 
confirms good transfer/blotting and suggests issues with the Runx2 primary antibody used. 
The possible problems may have been that the concentration of primary antibody used was 
too low or a cross-reactivity between the blocking agent and the primary antibody may have 
occurred.  
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Furthermore, it has been acknowledged that Runx2 triggers ALP activity (Lian et al., 2004), an 
early marker of osteogenic differentiation (Liu et al., 2011), so ALP activity was expected to be 
lower in cells transfected with miR-3148 lentivirus compared to the control and sponge. ALP 
degrades inorganic pyrophosphates, a major inhibitor of hydroxyapatite crystal growth, and 
releases phosphate (Kapustin et al., 2011) and it is generally a classic marker of osteogenic 
differentiation. Results from the ALP activity assay were inconclusive due to negative values 
and the presence of outliers. This may be the result of technical error with pipetting, a very 
low concentration of protein used, or an incorrect incubation period. 
Several calcification-related genes were found to be targets for the differentially expressed 
miRNAs at day 4, when a screen was performed using the software analysis programme 
StepOne Plus. Expression of the calcification genes BMP2, Sirt1, Sox9 and MMP16 in CASMCs 
transfected with control, miR-3148 and miR-3148 sponge lentivirus was investigated using 
total extracted RNA. BMP2 expression was expected to be lower under high miR-3148 activity 
compared to control and to correlate with the results for Runx2 expression as it induces the 
expression of Runx2 (Zhao et al., 2016), but the opposite was seen. BMP2 expression was 
lowest in control and highest in miR-3148 sponge lentivirus-transfected cells. As 
aforementioned, many miRNAs have the same target (e.g. Runx2 is downregulated by miR-
30b-d, but upregulated by miR-32) (Nanoudis et al., 2017) while a single miRNA may target 
more than one gene and affect different pathways with opposing results. Moreover, the target 
prediction of miR-3148 for BMP2 is very low (target prediction score: 0.7095) compared to 
Runx2, which means Runx2 expression was highly targeted compared to BMP2, explaining the 
difference in expression between the two genes. 
miR-3148 targets regulation of Sirt1 (target prediction score: 0.9855), a gene related to cell 
longevity and a marker for cell senescence (Takemura et al., 2011). Sirt1 downregulation has 
been observed in smooth muscle cells during osteoblastic differentiation (Takemura et al., 
2011). Recent studies have portrayed the correlation between increasing senescence-
associated secretory phenotype and increase in the tendency of VSMCs to undergo osteogenic 
differentiation (Takemura et al., 2011; Badi et al., 2018). In addition, senescent VSMCs are 
characterised by the expression of Runx2, among other bone-regulated genes (Badi et al., 
2018). A study conducted by Takemura et al. (2011) demonstrated Sirt1 to be an inhibitor of 
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vascular calcification by impeding VSMC senescence. Interestingly, this is contradicted by gene 
expression data from the present study which shows a reduced level of calcification in cells 
with downregulation of Sirt1 as a result of high miR-3148 activity, compared to control and 
miR-3148 sponge. This suggests that the miR-3148-mediated downregulation of Sirt1 does not 
have an effect on mineralisation and differentiation of CASMCs. This may be due to other 
aspects in this multifactorial disease. 
Sox9, a chondrogenic regulator primarily expressed in resting and proliferating chondrocytes, 
is also targeted by miR-3148 (target prediction score: 0.9905) (Zhang et al., 2012; Loebel et al., 
2015). It directly interacts with and represses the activity of Runx2. This is supported by the 
negative correlation seen between Sox9 and Runx2 gene expression and mineralisation levels 
under the different treatments of CASMCs in this study. The Runx2 and Sox9 gene expression 
under osteogenic conditions may reflect the interaction between the two transcription factors. 
Accordingly, an increase in Runx2/Sox9 ratio correlates with an increase in calcification and 
vice versa. Likewise, a lower Sox9 expression compared to Runx2 was detected in osteo-
chondroprogenitor cells differentiating towards osteogenic phenotypes during endochondral 
bone formation in mice (Akiyama et al., 2005). Sox9 binds to a target sequence on Runx2 and 
inhibits its function by either preventing protein degradation of the Runx2 gene or the 
activation of osteoblast-specific enhancers (Zhou et al., 2006; Cheng and Genever, 2010; 
Loebel et al., 2015). However, the correlation between Sox9 gene expression and Runx2 
protein could not be established due to poor Western blot results. Lowest expression of Sox9 
was expected in cells transfected with miR-3148 lentivirus, but the opposite was seen, this may 
be due to the low target prediction score for Sox9, as well as involvement of other factors 
regulating translation of the Sox9 gene. Future studies may involve elucidating the knockdown 
effects of Sox9 on various inhibitory genes to better the understanding of this regulatory 
network (Loebel et al., 2015). 
MMP16 gene translation is regulated by miR-3148 (target prediction score: 0.9995), so a 
reduced MMP16 expression was expected in cells in comparison to control and miR-3148 
sponge. However, this was not supported by the data produced in the present study. The 
highest MMP16 expression was observed in cells transfected with miR-3148 and the lowest in 
control. This suggests that changes in MMP16 may be due to Runx2-driven vascular 
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calcification. There is a positive correlation between expression of MMP16 and changes in 
calcification. Currently, no data is available on the association between MMP16 and Runx-2-
driven vascular calcification. More investigation is required to elucidate the mechanism of this 
enzyme in the current disease pathology. 
A reduction in calcification was also observed in cells transfected with lentivirus for miR-30d-
5p and -320a, but not in cells transfected with the sponge for these miRNAs, so this study 
focused on miR-3148. These results may be explained by the fact that miRNA sponges are able 
to inhibit all seed family members (Barta et al., 2016). In addition, miRNA sponges may display 
off-target effects by binding to unspecific miRNAs (Barta et al., 2016). On the other hand, each 
of the miRNAs are predicted to have hundreds of other targets, and are targeted by other 
components of the pathway, thus, regulation of calcification-related gene expression may 
involve a large network associated with other biological processes that work to maintain 
vascular homeostasis. 
5 Limitations of the study 
Several limitations are applicable to this study. Firstly, time constraints during this project did 
not allow for optimisation and completion of certain experiments including Western blot 
analysis and the ALP activity assay. It is essential to observe the effects of altered miR-3148 
activity on Runx2 protein level to confirm direct interaction with Runx2 protein. Previous 
research involving miR-204 has shown changes in Runx2 protein, but no change in Runx2 
mRNA translation in mouse and human mesenchymal stem cells (Huang et al., 2010). 
Moreover, in the current study, although it is shown that miR-3148 successfully reduces 
calcification, it does not show how the miRNA is modulated during the natural process of 
vascular calcification. 
In addition, primary cells were used for the experimental procedures. In an in vitro culture, 
primary human CASMCs experience dedifferentiation in response to high concentration of 
growth factors in the culture media (Worth et al., 2001). However, primary human cells have 
limitations which can lead to irreproducibility or formation of artefacts due to the fact that the 
cells have been removed from their microenvironment (Frismantiene et al., 2018). 
Furthermore, cells from different vascular beds have different properties and those from large 
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vessels like aortic smooth muscle cells have a greater plasticity than those from micro-vessels 
such as the CASMCs, where each can respond differently to the stimuli due to the nature of 
the heterogenic characteristics (Majesky, 2007). High heterogeneity can also be present in the 
same segment of the vessel, and therefore, inaccuracies in isolation of the tissue can cause 
high variability in primary culture (Frismantiene et al., 2018), making the experiment 
irreproducible. This variation in methods of CASMC isolation and cultivation can explain 
conflicting results between different laboratories (Alexander and Owens, 2012). Additionally, 
human CASMC isolates have a limited lifespan and are sensitive to handling and culture, in 
contrast to transformed cell lines. These isolates are prone to immediate senescence and are 
affected by donors’ age, gender and the applied treatments (Frismantiene et al., 2018).  
Moreover, in vitro studies eliminate environmental cues such as three-dimensionality and 
blood flow stimulation. In blood vessel walls VSMCs are elongated and arranged in an 
organised manner in a circumferential direction, whereas within in vitro cultures they are less 
elongated and randomly distributed on the culture plates (Chang et al., 2014). In addition, 
CASMCs could not be used beyond passage 8 due to their high tendency to undergo 
differentiation and change in phenotype. Research has shown that VSMCs undergo passage-
associated spontaneous phenotypic switching within in vitro culture studies, making it difficult 
to identify predictive markers of pathologic state (Chang et al., 2014). Despite these 
limitations, this study shows strong evidence of the effects of changes in miR-3148 activity on 
Runx2-regulated vascular calcification via osteogenic differentiation of CASMCs. 
6 Future Directions 
The current data shows long-term transfection of lentivirus in cultured CASMCs by assessment 
of GFP expression, suggesting stable increase in miRNA and miRNA sponge activity over the 
course of the calcification assay due to the ability of lentiviral vectors to integrate in the host 
cell genome (Segura et al., 2007). However, the level of miRNA in transfected cells was not 
determined, and this would need to be confirmed in future studies. Moreover, it has been 
suggested that certain miRNAs may have a tissue-specific nature of expression. An example of 
this is the opposite effects of miR-221-3p found in endothelial cells and VSMCs (Liu et al., 
2012). Another factor to consider is that certain miRNAs can behave differently in combination 
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with another. For example, a mouse study showed an increase in calcium deposition when 
miR-221 and -222 were combined, but not when applied separately (Mackenzie et al., 2014). 
Studies in the future could investigate the effects of altered miR-3148 activity in different cell 
types and in conjunction with other miRNAs within the vasculature on calcification-related 
gene expression. Moreover, a longitudinal study on the effect of changes in miR-3148 and 
onset of vascular calcification in SLE patients would be beneficial in helping to elucidate the 
mechanisms of miR-3148 in this pathology. 
Gateway® Cloning technology was used to produce destination vectors via the BP reaction. 
The production of this vector will allow the rapid production of miRNA and sponge expression 
constructs in the future. This cloning system is advantageous due to its rapid, high-throughput 
generation of Expression Clones and availability of a wide choice of open reading frames 
(Doyle, 2009). 
7 Conclusion 
This is the first study to investigate the regulatory role of EMV-derived miR-3148 in CAC via 
targeting Runx2 gene expression. Collectively, this report supports the hypothesis and suggests 
a protective role for miR-3148 against osteogenic differentiation of CASMCs and subsequent 
CAC in SLE patients. MV-associated miR-3148 is overexpressed in patients with SLE and it 
reduces osteogenic transdifferentiation of CASMCs in vitro when stimulated with βGP. This 
suggests that miR-3148 has a protective mechanism. However, a reduction in CAC does not 
necessarily translate into better clinical outcomes and cardiovascular risk is still high among 
this patient population, also signifying that the high level of miR-3148 is insufficient to be 
protective in this setting and a greater activity could be beneficial. The emerging role of EMVs 
and miRNAs is promising in reducing overall CVD mortality and morbidity, but further 
investigation is required to elucidate the precise effects of EMV-miRNA treatment of CAC. This 
will lead to a better understanding of the in vivo mechanisms of EMVs and miRNAs and their 
implications in drug designs against specific gene targets for the prevention or treatment of 
CAC. 
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